#USA #New York #Class Action #Levi Korsinsky #Replimune Group

Class Action Alert: Replimune Group, Inc. Under Legal Fire

In a significant development for shareholders of Replimune Group, Inc. (NASDAQ: REPL), Levi & Korsinsky LLP has announced a class action lawsuit against the biopharmaceutical company. The legal action arises on behalf of its investors who purchased shares between October 20, 2025, and April 10, 2026. This legal notification serves as an alert for shareholders to understand the implications and timeline of the case.

Background of the Case

The essence of the complaint is that Replimune allegedly misled its investors regarding the status of its RP1 application. The lawsuit claims that the company indicated its RP1 resubmission represented a complete and satisfactory response to the FDA's deficiencies. However, it subsequently became apparent that the FDA found the study design inadequate, leading to significant financial losses for shareholders.

According to the lawsuit, on December 8, 2025, REPL shares peaked at a high of $10.73. Following the FDA's Complete Response Letter—where the FDA outlined its disapproval—share prices plummeted. On April 10, 2026, shares closed at $4.76, marking a decline of nearly 19.5%. The downward spiral continued, with an additional 64.3% drop by April 13, 2026, resulting in a staggering cumulative loss of around $9.03 per share and an estimated 84% decrease in overall value.

Legal Context and Allegations

The lawsuit underscores serious concerns regarding whether Replimune disclosed the FDA's study design issues appropriately. The complaint details several elements that the FDA communicated but that the company allegedly failed to address adequately in its resubmissions:
1. Study Design Flaws: The FDA asserted that concerns over the single-arm RPL-001-16 trial were not rectified.
2. Response Criteria Discrepancies: It claimed that the response criteria used were inconsistent with recognized standards, thus challenging the results' credibility.
3. Inadequate Evidence: The resubmission's supporting data derived from an unplanned analysis covering only 10% of the intended patient population, raising questions about the robustness of the findings presented.

Legal experts assert that the language used in the company’s public statements failed to convey the specific known concerns raised by the FDA, which is pivotal for transparency with shareholders. As articulated by Joseph E. Levi, a leading attorney on the case, “Generic risk factor language cannot substitute for disclosing specific, known regulatory objections that a company has already received.” This highlights a critical aspect of investor relations—ensuring clarity and honesty about regulatory challenges.

Timelines and Shareholder Actions

The deadline for investors to apply for lead plaintiff status is set for October 5, 2026. Being a lead plaintiff means that an investor not only represents the interests of the entire class but also has significant influence over the progression and strategy of the lawsuit. Shareholders who believe they may qualify for recovery should prepare necessary documents, such as brokerage statements that demonstrate their transaction history with REPL shares during the specified class period.

Furthermore, it's essential for former shareholders and those who sold their shares at a loss to understand that eligibility for the lawsuit does not depend on current ownership of the shares but rather on the purchase timeframe during the defined period. This means that anyone who invested in REPL shares, irrespective of their current holding status, has the potential to seek recovery for their losses.

Conclusion

As the lawsuit progresses in the United States District Court for the District of Massachusetts, stakeholders will be closely monitoring Replimune Group's responses and the judicial outcomes. With the stakes this high, this case could set significant precedents for future securities litigation and investor transparency in the biopharmaceutical sector. Shareholders are urged to remain informed about the developments and consider their positions carefully as they navigate this complex legal landscape.